BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary

BLFS 11.12.2024

Full Press ReleaseSEC FilingsOur BLFS Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Navigating Current Standards and Compliance for Cell and Gene Therapy (CGT) Storage Containers
  • 01.13.2025 - BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations
  • 12.16.2024 - BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 3 Initial statement of beneficial ownership of securities
Investor Contact

Media & Investor Relations:
Troy Wichterman
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register hereto receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary

Strategic divestiture heightens focus on proprietary, higher-margin cell processing products

All-cash transaction fortifies balance sheet

BOTHELL, Wash.,Nov. 12, 2024/PRNewswire/ --BioLife Solutions, Inc. (NASDAQ: BLFS)("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for$73 millionin cash. SciSafe generated approximately$10.4 millionin revenue for the six months endedJune 30, 2024.

BioLife Solutions New Logo 2021 (PRNewsfoto/BioLife Solutions, Inc.)

"This divestiture marks another major step forward in our strategic refocus on our proprietary, higher-margin, recurring-revenue consumable solutions and away from non-core products and services," commentedRoderick de Greef, Chairman and CEO of BioLife Solutions. "BioLife purchased SciSafe in October of 2020 for$39 million, inclusive of earnout payments, and today's$73 millionsale is a solid return for shareholders that also provides significant capital to fuel our ongoing mission."

In conjunction with this transaction,Todd Berard, BioLife's Chief Marketing Officer, will assume all sales and marketing functions for the Company in the newly created position of Chief Commercial Officer. Berard has been with BioLife for more than 10 years and brings a proven skillset and established customer relationships to this expanded role.

Garrie Richardson, previously BioLife's Chief Revenue Officer for the last year, will join a now independent SciSafe as CEO. "Garrie joined BioLife through our acquisition of SciSafe and has been an integral part of our management team. We thank him for his service and extend our best wishes to the entire SciSafe team for their future success," added de Greef.

Stephens Inc. served as financial advisor and K&L Gates LLP served as legal counsel to BioLife for this transaction.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during their collection, development, storage and distribution. For more information, please visitwww.biolifesolutions.com, and follow BioLife onLinkedInandX.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available atwww.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Media & Investor Relations

At the Company

Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors

Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com

SOURCE BioLife Solutions, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com